Pharmacogenomics. 2009 Nov;10(11):1799-817.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR.

Source

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB# 7569, Kerr Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-27569, USA.

Abstract

Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subtherapeutic antiplatelet response. Clopidogrel is a prodrug that undergoes hepatic biotransformation by CYP2C19 into its active metabolite. Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events. Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response. Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness.

PMID:: 19891556; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. [JAMA. 2009]
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. JAMA. 2009 Aug 26; 302(8):849-57.
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. [JACC Cardiovasc Interv. 2008]
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, et al. JACC Cardiovasc Interv. 2008 Dec; 1(6):620-7.
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. [Pharmacogenet Genomics. 2010]
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, et al. Pharmacogenet Genomics. 2010 Jan; 20(1):18-25.
Review Factors associated with clopidogrel nonresponsiveness. [Future Cardiol. 2010]
Review Factors associated with clopidogrel nonresponsiveness.
Momary KM, Dorsch MP. Future Cardiol. 2010 Mar; 6(2):195-210.
Review Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? [Br J Clin Pharmacol. 2011]
Review Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
Ma TK, Lam YY, Tan VP, Yan BP. Br J Clin Pharmacol. 2011 Oct; 72(4):697-706.

See reviews... See all...

Cited by 2 PubMed Central articles

Review Personalized approaches to clopidogrel therapy: are we there yet? [Stroke. 2010]
Review Personalized approaches to clopidogrel therapy: are we there yet?
Anderson CD, Biffi A, Greenberg SM, Rosand J. Stroke. 2010 Dec; 41(12):2997-3002. Epub 2010 Oct 28.
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics. [PLoS Curr. 2010]
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.
Ned Mmsc Phd RM. PLoS Curr. 2010 Sep 20; 2. Epub 2010 Sep 20.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA ...
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
Pharmacogenomics. 2009 Nov ;10(11):1799-817.

PubMed
Observations on the Uganda I strain of Plasmodium malariae and Plasmodium brasil...
Observations on the Uganda I strain of Plasmodium malariae and Plasmodium brasilianum in Aotus and Saimiri monkeys and Anopheles mosquitoes.
J Parasitol. 2010 Apr ;96(2):329-39.

PubMed
The effects of weight bearing yoga training on the bone resorption markers of th...
The effects of weight bearing yoga training on the bone resorption markers of the postmenopausal women.
J Med Assoc Thai. 2009 Sep ;92 Suppl5:S102-8.

PubMed
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the ma...
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
J Manag Care Pharm. 2008 Oct ;14(8 Suppl):S3-28; quiz S30-1.

PubMed
Emergency surgical treatment for nonvariceal bleeding of the upper part of the g...
Emergency surgical treatment for nonvariceal bleeding of the upper part of the gastrointestinal tract.
Surg Gynecol Obstet. 1991 Feb ;172(2):113-20.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information